EW vs ABT Stock Comparison: AI Score, Valuation, Performance and Upside
EW and ABT represent focus and breadth in medical technology. Edwards is concentrated in heart valves, where it leads in transcatheter aortic replacement and is building newer mitral and tricuspid therapies. Abbott spans diagnostics, devices, nutrition, and pharmaceuticals, with glucose monitoring as its standout growth engine and a long dividend record.
Use this EW vs ABT comparison to decide how much you want a single clinical outcome to matter. At Edwards, trial results and reimbursement decisions in structural heart move the whole company. At Abbott, even a strong franchise like glucose monitoring is diluted by three other segments, which reduces both upside and downside.
ABT holds the edge across 3 of 5 key metrics in this comparison. EW has delivered stronger 1-year price return (+15.58% vs -24.35%), though ABT has the better forward P/E setup (16.81x vs 26.71x for EW). EW leads on both revenue growth (13.60%) and operating margin (29.84%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABT (+17.96%) than for EW (+11.92%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want concentrated exposure to structural heart therapy growth
- Believe mitral and tricuspid therapies will open large new patient populations
- Value the clinical evidence base behind its aortic valve leadership
- Accept single-therapy concentration and moderating core growth
- Want diversified healthcare exposure across four business segments
- Value the glucose monitoring franchise and its recurring sensor revenue
- Prefer a long dividend growth record
- Accept that diversification dilutes the impact of the best businesses
| Metric | EW | ABT |
|---|---|---|
| AI scorei | 42.3 | 49.8 |
| AI ranki | #863 | #502 |
| Latest closei | $86.29 | $101.29 |
| 1M returni | -4.95% | -11.23% |
| 6M returni | +8.76% | -2.60% |
| 1Y returni | +15.58% | -24.35% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EW | ABT |
|---|---|---|
| 1Y ago | $11.46K (+14.6%) started 2025-09-25 | $7.6K (-24.0%) started 2025-09-25 |
| 5Y ago | $7.37K (-26.3%) started 2021-09-27 | $9.69K (-3.1%) started 2021-09-27 |
| 10Y ago | $21.76K (+117.6%) started 2016-09-26 | $33.97K (+239.7%) started 2016-09-26 |
Hypothetical — past performance does not guarantee future results.
| Metric | EW | ABT |
|---|---|---|
| Market capi | $52B | $176.41B |
| Trailing P/Ei | 53.70 | 32.99 |
| Forward P/Ei | 26.71 | 16.81 |
| Price/Salesi | N/A | 5.49 |
| EV/Revenuei | 7.46 | 4.38 |
| Analyst targeti | $100.96 | $120.26 |
| Target upsidei | +11.92% | +17.96% |
| Metric | EW | ABT |
|---|---|---|
| Revenue growthi | 13.60% | 13.00% |
| Earnings growthi | -25.40% | -47.50% |
| EPS growthi | -25.40% | -47.50% |
| FCF margini | +18.92% | +15.48% |
| Operating margini | 29.84% | 14.71% |
| Profit margini | 15.43% | 11.65% |
| ROIC proxyi | 9.18% | 10.58% |
| Return on equityi | 9.18% | 10.58% |
| Dividend yieldi | N/A | 2.47% |
| Payout ratioi | 0.00% | 78.96% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 0.85 | 0.59 |
| Debt/equityi | 6.57 | 63.21 |
| Current ratioi | 4.52 | 1.38 |
| Quick ratioi | 3.45 | 0.80 |
Over the past year, EW and ABT have moved weakly in the same direction (correlation of 0.30), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | EW | ABT |
|---|---|---|---|
| 1Y | Growthi | +14.64% | -24.02% |
| CAGRi | +14.66% | -24.05% | |
| Volatilityi | 25.22% | 26.80% | |
| Sharpe ratioi | 0.49 | -1.06 | |
| Sortino ratioi | 0.74 | -1.46 | |
| Max drawdowni | 13.19% | 38.66% | |
| Current drawdowni | 9.34% | 24.74% | |
| Avg drawdowni | 4.43% | 18.56% | |
| Ulcer Indexi | 5.58% | 21.51% | |
| Max daily dropi | 3.64% | 10.04% | |
| Max wkly dropi | 7.40% | 13.11% | |
| 5Y | Growthi | -26.29% | -9.91% |
| CAGRi | -5.92% | -2.07% | |
| Volatilityi | 32.80% | 23.03% | |
| Sharpe ratioi | -0.15 | -0.17 | |
| Sortino ratioi | -0.19 | -0.24 | |
| Max drawdowni | 54.32% | 40.85% | |
| Current drawdowni | 33.97% | 27.43% | |
| Avg drawdowni | 34.54% | 17.60% | |
| Ulcer Indexi | 36.52% | 19.87% | |
| Max daily dropi | 31.34% | 10.04% | |
| Max wkly dropi | 30.43% | 13.11% | |
| 10Y | Growthi | +117.65% | +185.45% |
| CAGRi | +8.09% | +11.06% | |
| Volatilityi | 32.27% | 24.02% | |
| Sharpe ratioi | 0.27 | 0.37 | |
| Sortino ratioi | 0.36 | 0.53 | |
| Max drawdowni | 54.32% | 40.85% | |
| Current drawdowni | 33.97% | 27.43% | |
| Avg drawdowni | 21.17% | 10.89% | |
| Ulcer Indexi | 26.91% | 14.60% | |
| Max daily dropi | 31.34% | 10.04% | |
| Max wkly dropi | 30.43% | 16.72% |
| Category | EW | ABT |
|---|---|---|
| Company | Edwards Lifesciences Corporation | Abbott Laboratories |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | Specialist in heart valve therapies, dominated by transcatheter aortic valve replacement, with surgical valves and a growing transcatheter mitral and tricuspid business treating other heart valve conditions. | Diversified healthcare company across diagnostics, medical devices including continuous glucose monitoring and structural heart, nutrition products, and established pharmaceuticals sold largely in international markets. |
| Investor focus | Transcatheter aortic valve procedure growth, mitral and tricuspid therapy adoption and reimbursement, clinical trial outcomes in earlier-stage patients, and competitive share. | Continuous glucose monitoring growth, diagnostics normalisation after testing-driven surges, device segment performance, nutrition recovery, and dividend growth. |
- Leading position in transcatheter aortic valves with deep clinical evidence behind it
- Mitral and tricuspid therapies open large, largely untreated patient populations
- Focused portfolio means clinical and commercial wins move results directly
- Continuous glucose monitoring is a large, fast-growing franchise with recurring sensor revenue
- Four distinct business segments provide genuine diversification
- Long dividend growth record supported by broad, stable cash generation
- Aortic valve growth has moderated as the core indication matured
- Reliant on procedure growth and hospital capacity, including trained specialist availability
- Concentrated in one therapy area, so a competitive or clinical setback matters greatly
- Diagnostics revenue fell sharply as pandemic testing demand faded, complicating comparisons
- Nutrition business has faced manufacturing and litigation issues
- Diversification means strong segments are diluted by weaker ones
Compare more than two at a time
This page is a fixed writeup on EW and ABT. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside EW and ABT, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.